Jinhe Biotechnology CO., LTD. (SZSE: 002688)
Health Care · Pharmaceuticals · CN
CN¥5.17
-0.58% today · -29.3% 1Y
Jinhe Biotechnology CO., LTD. (SZSE: 002688) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $581.17M and employs 2,718 people.
Over the last twelve months the share price has lost 29.3%, trading between 4.58 and 7.71.
Tweenvest scores Jinhe Biotechnology CO., LTD. across four factors: quality 69/100, value 48/100, growth 41/100, dividend 42/100. Its strongest factor is quality.
002688 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $581.17M
- Revenue (TTM)
- $434.20M
- P/E
- 104.09
- EPS
- 0.05
- Dividend yield
- 1.93%
- Beta (5Y)
- 0.33
- 52-week high
- CN¥7.71
- 52-week low
- CN¥4.58
- Avg volume (3M)
- —
- Shares outstanding
- 755.68M
- Employees
- 2,718
- Next earnings
- —
About Jinhe Biotechnology CO., LTD.
Founded in 1990 and headquartered in Dalian, China, Jinhe Biotechnology Co. Ltd. focuses on the development and distribution of animal health pharmaceuticals both domestically and internationally. The company provides chlortetracycline in a feed-grade formulation, an antimicrobial compound vital for preventing and treating conditions like white dysentery, enteritis, pneumonia, typhoid, paratyphoid, and cholera in poultry and livestock. Additionally, its offerings include chlortetracycline hydrochloride, utilized to combat pullorum disease, typhoid, swine enteritis, and other bacterial ailments such as paratyphoid and cholera. Jinhe Biotechnology extends its market reach globally, exporting these veterinary solutions to regions including the United States, Southeast Asia, Latin America, and Europe.
- ISIN
- CNE100001HK7
- Founded
- 1990
- Listed since
- Jul 13, 2012
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,237.51 | -1.43% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $272.29 | +0.76% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.48 | -1.36% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.10 | -1.73% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.32 | -1.70% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.89 | -0.64% |
Figures last refreshed Aug 18, 2026.